Preoperative cardiac risk assessment: Difference between revisions
No edit summary |
(/* ACCF/AHA 2011 Guidelines for Percutaneous Coronary Intervention: Revascularization Before Non-cardiac Surgery{{cite journal |author=Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg...) |
||
Line 579: | Line 579: | ||
|} | |} | ||
===ACCF/AHA 2011 Guidelines for Percutaneous Coronary Intervention: Revascularization Before Non-cardiac Surgery< | ===ACCF/AHA 2011 Guidelines for Percutaneous Coronary Intervention: Revascularization Before Non-cardiac Surgery<ref name="pmid22070837">{{cite journal |author=Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH |title=2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions |journal=[[Journal of the American College of Cardiology]] |volume=58 |issue=24 |pages=2550–83 |year=2011|month=December|pmid=22070837|doi=10.1016/j.jacc.2011.08.006|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(11)02875-0|accessdate=2011-12-08|url=http://content.onlinejacc.org/cgi/reprint/58/24/2550.pdf|PDF}}</ref>(DO NOT EDIT)=== | ||
Revision as of 19:05, 30 October 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Mohammed A. Sbeih, M.D. [2]; Kashish Goel,M.D.
Pre-operative cardiac risk assessment Microchapters |
Cardiac risk stratification for noncardiac surgical procedures |
---|
ACC / AHA recommendations for perioperative cardiac assessment |
Preoperative cardiac risk assessment On the Web |
Stepwise Approach to Pre-operative Cardiac Assessment
Adapted from Fleisher et al. Circulation. 2009 Nov 24;120(21):e169-276[1]; HR, Heart rate
§,∧ Noninvasive testing is not useful for patients with no clinical risk factors undergoing intermediate-risk or low-risk noncardiac surgery (AHA guidelines Class III, Level of Evidence: C).
¶ Clinical risk factors: Ischemic heart disease, compensated or prior heart failure, diabetes mellitus, renal insufficiency, and cerebrovascular disease
Cardiac Risk Index
Original / Goldman Index
Goldman et.al devised a cardiac index for preoperative evaluation in 1977. [2]
Risk Factors | Points |
---|---|
History | |
Age > 70 years | 5 |
Recent MI (6 months) | 10 |
Aortic Stenosis | 3 |
Physical Examination | |
Signs of Chronic Heart Failure | 11 |
Electrocardiogram | |
Rhythm other than Sinus Rhythm | 7 |
PVC's > 5/ min | 7 |
Poor General Medical Condition | |
PO2 < 60mmHg; PCO2 > 50mmHg; K < 3mmol/l; HCO3 < 20mmol/l; urea >18mmol/l (BUN > 50mg/dl); Creatinine > 260umol/l (3mg/dl); bedridden from non-cardiac cause | 3 |
Surgery | |
Emergency | 4 |
Intrathoracic | 3 |
Total Points | 53 |
Goldman
Classification |
Total
Points |
---|---|
1 | 0 - 5 |
2 | 6 - 12 |
3 | 13 - 25 |
4 | > 25 |
Revised Cardiac Risk Index
- Identification of patients at high rate of complications who are undergoing elective cardiac surgery.
- Risk stratification with non invasive techniques.[3]
Revised Cardiac Risk Index |
---|
1. History of Ischemic Heart Disease |
2. History of Congestive Heart Failure |
3. History of Cerebrovascular Disease |
4. Insulin Therapy for Diabetes |
5. Renal Insufficiency |
6. High Risk Type Surgery |
- Rates of major cardiac complications increased with 2 or more risk factors of revised cardiac risk index.[3]
Surgery Specific Risk - 2007 ACC/AHA guidelines
- Vascular surgery has a risk more than 5%
- Aortic surgeries
- Peripheral vascular surgery
- Intermediate risk surgeries are as follows:(1- 5% risk)
- Intraperitoneal
- Intrathoracic
- Carotid endarterectomy
- Head and neck surgery
- Orthopedic surgery
- Prostate surgery
- Low risk:(< 1%)
- Endoscopic procedures
- Superficial procedures
- Cataract surgery
- Breast surgery
- Ambulatory surgery
Cardiac Conditions with Increased Pre-operative Risk
1. Unstable Coronary Syndromes
- Unstable or severe angina (Canadian Cardiovascular Society class III or IV): May include “stable” angina in patients who are unusually sedentary.
- Recent MI: Greater than 7 days, but less than or equal to 1 month (within 30 days)
2. Decompensated HF
- NYHA functional class IV
- Worsening or new-onset heart failure
3. Significant Arrhythmias
- Mobitz II atrioventricular block
- Third degree AV block
- Symptomatic ventricular arrhythmias
- Supraventricular arrhythmias (including atrial fibrillation) with uncontrolled ventricular rate (HR greater than 100 bpm at rest)
- Symptomatic bradycardia
- Newly recognized ventricular tachycardia
4. Severe Valvular Disease
- Severe aortic stenosis (mean pressure gradient >40 mm Hg, aortic valve area <1.0 cm2, or symptomatic)
- Symptomatic mitral stenosis (progressive dyspnea on exertion, exertional presyncope, or heart failure)
Estimated Energy Requirements for Various Activities
The metabolic equivalent of task (MET), or simply metabolic equivalent, is a physiological concept expressing the energy cost of physical activities[4] as multiples of resting metabolic rate (RMR) and is defined as the ratio of metabolic rate (and therefore the rate of energy consumption) during a specific physical activity to a reference rate of metabolic rate at rest, set by convention to 3.5 ml O2·kg-1·min-1 or equivalently 1 kcal·kg-1· h-1 or 4.184 kJ·kg-1· h-1. By convention 1 MET is considered as the resting metabolic rate obtained during quiet sitting[5][6] . MET values of physical activities range from 0.9 (sleeping) to 18 (running at 17.5 km/h or a 5:31 mile pace).
Calculating the Weekly Energy Expended in Recreational-time Physical Activity using METs (Metabolic equivalent task) [7].
Physical Activity | MET |
---|---|
Light Intensity Activities | < 3 |
Sleeping | 0.9 |
Watching television | 1.0 |
Writing, desk work, typing | 1.8 |
Walking, 1.7 mph (2.7 km/h), level ground, strolling, very slow | 2.3 |
Walking, 2.5 mph (4 km/h) | 2.9 |
Moderate Intensity Activities | 3 to 6 |
Bicycling, stationary, 50 watts, very light effort | 3.0 |
Walking 3.0 mph (4.8 km/h) | 3.3 |
Calisthenics, home exercise, light or moderate effort, general | 3.5 |
Walking 3.4 mph (5.5 km/h) | 3.6 |
Bicycling, <10 mph (16 km/h), leisure, to work or for pleasure | 4.0 |
Bicycling, stationary, 100 watts, light effort | 5.5 |
Vigorous Intensity Activities | > 6 |
Jogging, general | 7.0 |
Calisthenics (e.g. pushups, situps, pullups,jumping jacks), heavy, vigorous effort | 8.0 |
Running jogging, in place | 8.0 |
Rope jumping | 10.0 |
Cardiac Risk Stratification for Non-cardiac Surgical Procedures
High (Reported cardiac risk often greater than 5%)
- Aortic and other major vascular surgery.
- Peripheral vascular surgery.
- Anticipated prolonged surgical procedures associated with large fluid shifts and/or blood loss.
Intermediate (Reported cardiac risk generally 1% to 5%)
- Carotid endarterectomy.
- Head and neck surgery.
- Intraperitoneal and intrathoracic surgery.
- Orthopedic surgery.
- Prostate surgery.
Low (Reported cardiac risk generally less than 1%)
- Endoscopic procedures.
- Superficial procedure.
- Cataract surgery.
- Breast surgery.
- Ambulatory surgery
2007 ACC/AHA Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Preoperative Cardiac Assessment[8] (DO NOT EDIT)
Risk Factors | Functional Capacity | Vascular Surgery (High Risk) | Intermediate Risk Surgery | Low Risk Surgery |
---|---|---|---|---|
0 | < 4 | Proceed with surgery |
Proceed with surgery |
Proceed with surgery |
0 | >= 4 | Proceed with surgery |
Proceed with surgery |
Proceed with surgery |
1 or 2 | < 4 | Proceed with surgery and heart rate control |
Proceed with surgery and heart rate control |
Proceed with surgery |
1 or 2 | >= 4 | Proceed with surgery and heart rate control |
Proceed with surgery and heart rate control |
Proceed with surgery |
>= 3 | < 4 | Non-invasive Stress Test (NST) |
Proceed with surgery and heart rate control |
Proceed with surgery |
>= 3 | >= 4 | Proceed with surgery and heart rate control |
Proceed with surgery and heart rate control |
Proceed with surgery |
Adapted from lecture of Robert B.McCully,M.D.;
Class I recommendation | Class IIa recommendation |
Class I |
1.Patients who have a need for emergency noncardiac surgery should proceed to the operating room and continue perioperative surveillance and postoperative risk :stratification and risk factor management. (Level of Evidence: C) |
2.Patients with active cardiac conditions* should be evaluated and treated per ACC/AHA guidelines and, if appropriate, consider proceeding to the operating room. (Level of Evidence: B) |
3.Patients undergoing low risk surgery are recommended to proceed to planned surgery.† (Level of Evidence: B) |
4.Patients with poor (less than 4 METs) or unknown functional capacity and no clinical risk factors should proceed with planned surgery.† (Level of Evidence: B) |
Class IIa |
1.It is probably recommended that patients with functional capacity greater than or equal to 4 METs without symptoms‡ proceed to planned surgery.§ (Level of Evidence: B) |
2.It is probably recommended that patients with poor (less than 4 METs) or unknown functional capacity and 3 or more clinical risk factors who are scheduled for vascular surgery consider testing if it will change management.¶ (Level of Evidence: B) |
3.It is probably recommended that patients with poor (less than 4 METs) or unknown functional capacity and 3 or more clinical risk factors who are scheduled for intermediate risk surgery proceed with planned surgery with heart rate control.¶ (Level of Evidence: B) |
4.It is probably recommended that patients with poor (less than 4 METs) or unknown functional capacity and 1 or 2 clinical risk factors who are scheduled for vascular or intermediate risk surgery proceed with planned surgery with heart rate control.¶ (Level of Evidence: B) |
Class IIa |
1.Noninvasive testing might be considered if it will change management for patients with poor (less than 4 METs) or unknown functional capacity and 3 or more clinical risk factors who are scheduled for intermediate risk surgery. (Level of Evidence: B) |
2.Noninvasive testing might be considered if it will change management for patients with poor (less than 4 METs) or unknown functional capacity and 1 or 2 clinical risk factors who are scheduled for vascular or intermediate risk surgery. (Level of Evidence: B) |
§Noninvasive testing may be considered before surgery in specific patients with risk factors if it will change management. Clinical risk factors include ischemic heart disease, compensated or prior heart failure, diabetes mellitus, renal insufficiency, and cerebrovascular disease. ¶Consider perioperative beta blockade for populations in which this has been shown to reduce cardiac morbidity/mortality.
- Key points about NST
- No Class I recommendation
- Class IIa recommendation in patients with
- >= 3 risk factors
- Functional capacity of < 4 METs
- High risk surgery (Vascular surgery)
2007 ACC/AHA Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Recommendations for Non-invasive Evaluation of Left Ventricular Function [8] (DO NOT EDIT)
Class III (No Benefit) |
1. Routine perioperative evaluation of LV function in patients is not recommended.(Level of Evidence: B) |
Class IIa |
1.It is reasonable for patients with dyspnea of unknown origin to undergo preoperative evaluation of left ventricular (LV) function. (Level of Evidence: C) |
2.It is reasonable for patients with current or prior heart failure with worsening dyspnea or other change in clinical status to undergo preoperative evaluation of LV function if not performed within 12 months (Level of Evidence: C) |
Class IIb |
1. Reassessment of LV function in clinically stable patients with previously documented cardiomyopathy is not well established. (Level of Evidence: C) |
Pre-operative Stress Testing
- For patients who are able to exercise : Treadmill Exercise ECG.
- For patients who are unable to exercise : Pharmacological Stress Imaging.
Electrocardiogram - Treadmill Exercise ECG
Risk | METs | Heart rate |
---|---|---|
High Risk - Ischemia induced by low level of exercise | < 4 | < 100 or 70% age pred. max |
Intermediate Risk - Ischemia induced by moderate exercise | 4 - 6 | > 100 - 130 or 70 - 85% of age pred. max |
Low Risk - No ischemia or ischemia induced at higher level of exercise | > 7 | > 130 or > 85% of age pred. max |
Inadequate test : In patients undergoing non cardiac surgery ,the inabilty to exercise to a level of 4 - 6 METs without out ischemia should be considered as inadequate test. (Stage II Bruce protocol)
Pre-operative 12 Lead ECG
- The time frame for ECG testing is fixed, it can be done within 30 days of planned surgery when indicated.
- The resting 12-lead ECG did not identify increased perioperative risk in patients undergoing low-risk surgery.
- In patients with coronary disease, the resting 12-lead ECG may have contains important prognostic information relating to long-term morbidity and mortality.
2007 ACC/AHA Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Recommendations for Preoperative Resting 12 - Lead ECG[8] (DO NOT EDIT)
Class I |
1. Preoperative resting 12-lead ECG is recommended for patients with at least 1 clinical risk factor who are undergoing vascular surgical procedures. (Level of Evidence: B) |
2. Preoperative resting 12-lead ECG is recommended for patients with known CHD, peripheral arterial disease, or cerebrovascular disease who are undergoing intermediate-risk surgical procedures. (Level of Evidence: C) |
Class III (No Benefit) |
1. Preoperative and postoperative resting 12-lead ECGs are not indicated in asymptomatic persons undergoing low-risk surgical procedures. (Level of Evidence: B) |
Class IIa |
1. Preoperative resting 12-lead ECG is reasonable in persons with no clinical risk factors who are undergoing vascular surgical procedures. (Level of Evidence: B) |
Class IIb |
1. . Preoperative resting 12-lead ECG may be reasonable in patients with at least 1 clinical risk factor who are undergoing intermediate-risk operative procedures. (Level of Evidence: B) |
Non invasive Stress Testing (NST)
These are used for preoperative evaluation of patients undergoing non cardiac surgery. These are used in patients who cannot exercise.
- Techniques
- Increasing oxygen demand of the heart either by pacing or inotropes
- Increasing blood supply (hyperemic response) by vasodilators
Dobutamine Stress Echocardiography
- Increasing doses of supratherapeutic doses of dobutamine are infused , which increases myocardial contractility and heart rate. This leads to significant coronary stenosis which can be identified by regional wall-motion abnormalities within the distribution of the affected vessels.
- It has high negative predictive value (93-100%)
- It has low positive predicitive value (5 - 33%)
- Extent of regional wall motion abnormality and low threshold of ischemia is an important predictor of post operative events.
Radionuclide Myocardial Perfusion Imaging
- Stress nuclear myocardial perfusion imaging has a high sensitivity for detecting patients at risk for perioperative cardiac events.
- It has high negative predictive value (95-100%)
- It has low positive predictive value (5- 20%)
- Perioperative cardiac risk is directly proportional to the myocardium at risk detected by the extent of reversible defects found on imaging.
- It is of high clinical value when used for selective population of high clinical risk.
In Left Bundle-Branch Block
- Exercise may at times induce reversible septal defects in the absence of LAD disease. Specificity of exercise myocardial perfusion imaging in presence of LBBB is low.
- Pharmacologic strss testing with perfusion scintigraphy or DSE is preferred over exercise stress testing.
ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Noninvasive Stress Testing Before Noncardiac Surgery[8] (DO NOT EDIT)
Class I |
1. Patients with active cardiac conditions (see Table 2) in whom noncardiac surgery is planned should be evaluated and treated per ACC/AHA guidelines before noncardiac surgery. (Level of Evidence: B) |
Class III (No Benefit) |
1. Noninvasive testing is not useful for patients with no clinical risk factors undergoing intermediate-risk noncardiac surgery. (Level of Evidence: C) |
2. Noninvasive testing is not useful for patients undergoing low-risk noncardiac surgery. (Level of Evidence: C) |
Class IIa |
1. Noninvasive stress testing of patients with 3 or more clinical risk factors and poor functional capacity (less than 4 METs) who require vascular surgery is reasonable if it will change management. (Level of Evidence: B) |
Class IIb |
1. Noninvasive stress testing may be considered for patients with at least 1 to 2 clinical risk factors and poor functional capacity (less than 4 METs) who require intermediate-risk noncardiac surgery if it will change management. (Level of Evidence: B) |
2. Noninvasive stress testing may be considered for patients with at least 1 to 2 clinical risk factors and good functional capacity (greater than or equal to 4 METs) who are undergoing vascular surgery. (Level of Evidence: B) |
Perioperative Revascularization Therapy
Routine prophylactic coronary revascularization is not recommended. (Class III) |
- Extensive ischemia is a risk factor for increased peri-operative events
- Pre-op coronary revascularization does not prevent death or MI. [9]
Pre-operative CABG
- Patients who have high-risk coronary anatomy and in whom long-term outcome would likely be improved by CABG should generally undergo coronary revascularization before a noncardiac elective vascular surgical procedure or noncardiac operative procedures of intermediate or high risk. [10]
- The cumulative mortality and morbidity of both the coronary revascularization procedure and the noncardiac surgery should be weighed carefully. The individual patient’s overall health,functional status, and prognosis have to be taken into consideration. [11]
Pre-operative PCI
- Prophylactic preoperative PCI in non cardiac surgical procedures is of no value in preventing perioperative cardiac events. [12]
- Unscheduled noncardiac surgery in a patient who has undergone a prior PCI presents special challenges, particularly with regard to management of the dual-antiplatelet agents required in those who have received coronary stents.
- Following flowchart depicts the approach based on expert opinion[13] in patients who have undergone successful coronary intervention with or without stent placement before planned or unplanned noncardiac surgery.
Prior PCI | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balloon Angioplasty | Bare Metal Stent | Drug | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Time since PCI < 14 days | Time since PCI > 14 days | Time since PCI > 30-45 days | Time since PCI < 30-45 days | Time since PCI < 365 days | Time since PCI > 365 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Delay for elective surgery | Proceed to operating room with aspirin | Delay for elective surgery | Proceed to operating room with aspirin | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Perioperative Medical Therapy
Beta Blockers
Key points about perioperative beta blocker therapy
- Start well before surgery. ( minimum of 1 week - don't start on the day of surgery)
- Use is in high or intermediate risk population only.
- Titrate dose to heart rate and blood pressure starting with a low dose. (Fixed doses shouldn't be used)
- Long acting betablockers are better to use.
- If intra-operative heat rate goes above 80 start IV administration.(Look for alternative causes of tachycardia)
For more information on perioperative betablocker therapy click here.
ACCF/AHA 2009 Guidelines - Focused Update on Recommendations for Perioperative Beta Blockade[14] (DO NOT EDIT)
Class I |
1. Continue beta blocker in patients already taking them. |
Class IIa |
1. Titrate beta blocker to heart rate, blood pressure in patients undergoing vascular(high risk) or intermediate risk surgery who are at high risk(CAD, >= 2 risk factors). |
Statins
- Statins have protective effective on cardiac complications in non cardiac surgery, but the dosage and the target levels are unclear.
- Utilizing the perioperative period as an opportunity to impact long-term health, consideration should be given to starting statin therapy in
patients who meet National Cholesterol Education Program criteria.
ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Recommendations for Statin Therapy[13] (DO NOT EDIT)
Class I |
" 1. For patients currently taking statins and scheduled for noncardiac surgery, statins should be continued.(Level of Evidence: B) " |
Class IIa |
"1. For patients undergoing vascular surgery with or without clinical risk factors, statin use is reasonable.(Level of Evidence: B) " |
Class IIb |
" 1. For patients with at least 1 clinical risk factor who are undergoing intermediate-risk procedures, statins may be considered. (Level of Evidence: C) " |
Alpha 2 Agonists
- Strong evidence is lacking for the recommendation of clonidine for blood pressure control.
- Administration of clonidine had minimal effects on hemodynamics and post operative mortality.
ACC / AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Alpha- 2 agonists[13] (DO NOT EDIT)
Class III (No Benefit) |
" 1. Alpha-2 agonists should not be given to patients undergoing surgery who have contraindications to this medication. (Level of Evidence: C) " |
Class IIb |
"1. Alpha-2 agonists for perioperative control of hypertension may be considered for patients with known CAD or at least 1 clinical risk factor who are undergoing surgery. (Level of Evidence: A) " |
ACCF/AHA 2011 Guidelines for Percutaneous Coronary Intervention: Revascularization Before Non-cardiac Surgery[15] (DO NOT EDIT)
Class III (No Benefit) |
"1. Routine prophylactic coronary revascularization should not be performed in patients with stable CAD before noncardiac surgery.[16][17] (Level of Evidence: B)" |
"2. Elective non-cardiac surgery should not be performed in the 4 to 6 weeks after balloon angioplasty or BMS implantation or the 12 months after DES implantation in patients in whom the P2Y12 inhibitor will need to be discontinued peri-operatively.[18][19][20][21](Level of Evidence: B)" |
Class IIa |
"1. 1. For patients who require PCI and are scheduled for elective non-cardiac surgery in the subsequent 12 months, a strategy of balloon angioplasty, or BMS implantation followed by 4 to 6 weeks of dual antiplatelet therapy (DAPT), is reasonable.[22][23][24][20][25][19][26](Level of Evidence: B)" |
"2. For patients with drug eluting stent (DES) who must undergo urgent surgical procedures that mandate the discontinuation of dual antiplatelet therapy (DAPT), it is reasonable to continue aspirin if possible and restart the P2Y12 inhibitor as soon as possible in the immediate postoperative period.[24][13] (Level of Evidence: C)" |
ACCF/AHA 2011 Guidelines for Percutaneous Coronary Intervention: Revascularization Before Non-cardiac Surgery[15](DO NOT EDIT)
Class I |
" 1. Coronary revascularization before noncardiac surgery is useful in patients with stable angina who have significant left main coronary artery stenosis (Level of Evidence: A) " |
" 2. Coronary revascularization before noncardiac surgery is useful in patients with stable angina who have 3-vessel disease. (Survival benefit is greater when left ventricular ejection fraction is less than 0.50.) (Level of Evidence: A) "
|
" 3. Coronary revascularization before noncardiac surgery is useful in patients with stable angina who have 2-vessel disease with significant proximal left anterior descending stenosis and either ejection fraction less than 0.50 or demonstrable ischemia on noninvasive testing (Level of Evidence: A) "
|
References
- ↑ Fleisher LA, Beckman JA, Brown KA; et al. (2009). "2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American college of cardiology foundation/American heart association task force on practice guidelines". Circulation. 120 (21): e169–276. doi:10.1161/CIRCULATIONAHA.109.192690. PMID 19884473. Unknown parameter
|month=
ignored (help) - ↑ Goldman L, Caldera DL, Nussbaum SR, Southwick FS, Krogstad D, Murray B, Burke DS, O'Malley TA, Goroll AH, Caplan CH, Nolan J, Carabello B, Slater EE (1977). "Multifactorial index of cardiac risk in noncardiac surgical procedures". The New England Journal of Medicine. 297 (16): 845–50. doi:10.1056/NEJM197710202971601. PMID 904659. Retrieved 2012-10-11. Unknown parameter
|month=
ignored (help) - ↑ 3.0 3.1 Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, Sugarbaker DJ, Donaldson MC, Poss R, Ho KK, Ludwig LE, Pedan A, Goldman L (1999). "Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery". Circulation. 100 (10): 1043–9. PMID 10477528. Retrieved 2012-10-11. Unknown parameter
|month=
ignored (help) - ↑ Physical activity can be defined as “bodily movement produced by the contraction of skeletal muscle that increases energy expenditure above the basal level”
- ↑ Ainsworth et al., 1993
- ↑ Ainsworth et al., 2000.
- ↑ Adapted from Compendium of Physical Activities. Ainsworth, BE et al. Medicine and Science in Sports and Exercise. Vol 25, Pg 713 (1993) and Vol 32, S498 (2000).
- ↑ 8.0 8.1 8.2 8.3 Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE; et al. (2007). "ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery". Circulation. 116 (17): e418–99. doi:10.1161/CIRCULATIONAHA.107.185699. PMID 17901357.
- ↑ Garcia S, Rider JE, Moritz TE, Pierpont G, Goldman S, Larsen GC, Shunk K, Littooy F, Santilli S, Rapp J, Reda DJ, Ward HB, McFalls EO (2011). "Preoperative coronary artery revascularization and long-term outcomes following abdominal aortic vascular surgery in patients with abnormal myocardial perfusion scans: a subgroup analysis of the coronary artery revascularization prophylaxis trial". Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions. 77 (1): 134–41. doi:10.1002/ccd.22699. PMID 20602474. Retrieved 2012-10-12. Unknown parameter
|month=
ignored (help) - ↑ "Guidelines and indications for coronary artery bypass graft surgery. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Coronary Artery Bypass Graft Surgery)". Journal of the American College of Cardiology. 17 (3): 543–89. 1991. PMID 1993774. Unknown parameter
|month=
ignored (help);|access-date=
requires|url=
(help) - ↑ Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter AM, Lytle BW, Marlow RA, Nugent WC, Orszulak TA, Antman EM, Smith SC, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Ornato JP (2004). "ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery)". Journal of the American College of Cardiology. 44 (5): e213–310. doi:10.1016/j.jacc.2004.07.021. PMID 15337239. Retrieved 2012-10-12. Unknown parameter
|month=
ignored (help) - ↑ Smith SC, Feldman TE, Hirshfeld JW, Jacobs AK, Kern MJ, King SB, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Smith SC, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B (2006). "ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)". Journal of the American College of Cardiology. 47 (1): e1–121. doi:10.1016/j.jacc.2005.12.001. PMID 16386656. Retrieved 2012-10-12. Unknown parameter
|month=
ignored (help) - ↑ 13.0 13.1 13.2 13.3 Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof EL, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW (2007). "ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery". Journal of the American College of Cardiology. 50 (17): 1707–32. doi:10.1016/j.jacc.2007.09.001. PMID 17950159. Retrieved 2012-10-12. Unknown parameter
|month=
ignored (help) - ↑ Fleischmann KE, Beckman JA, Buller CE, Calkins H, Fleisher LA, Freeman WK; et al. (2009). "2009 ACCF/AHA focused update on perioperative beta blockade: a report of the American college of cardiology foundation/American heart association task force on practice guidelines". Circulation. 120 (21): 2123–51. doi:10.1161/CIRCULATIONAHA.109.192689. PMID 19884474.
- ↑ 15.0 15.1 Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH (2011). "2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions" (PDF). Journal of the American College of Cardiology. 58 (24): 2550–83. doi:10.1016/j.jacc.2011.08.006. PMID 22070837. Retrieved 2011-12-08. Text "PDF" ignored (help); Unknown parameter
|month=
ignored (help) - ↑ Cinà CS, Devereaux PJ (2006). "Coronary-artery revascularization before elective major vascular surgery. McFalls EO, ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, Pierpont G, Santilli S, Rapp J, Hattler B, Shunk K, Jaenicke C, Thottapurathu L, Ellis N, Reda DJ, Henderson WG. N Engl J Med. 2004; 351: 2795-804". Vascular Medicine (London, England). 11 (1): 61–3. PMID 16669417. Retrieved 2011-12-08. Unknown parameter
|month=
ignored (help) - ↑ Schouten O, van Kuijk JP, Flu WJ, Winkel TA, Welten GM, Boersma E, Verhagen HJ, Bax JJ, Poldermans D (2009). "Long-term outcome of prophylactic coronary revascularization in cardiac high-risk patients undergoing major vascular surgery (from the randomized DECREASE-V Pilot Study)". The American Journal of Cardiology. 103 (7): 897–901. doi:10.1016/j.amjcard.2008.12.018. PMID 19327412. Retrieved 2011-12-08. Unknown parameter
|month=
ignored (help) - ↑ Grines CL, Bonow RO, Casey DE, Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P (2007). "Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians". Journal of the American College of Cardiology. 49 (6): 734–9. doi:10.1016/j.jacc.2007.01.003. PMID 17291948. Retrieved 2011-12-08. Unknown parameter
|month=
ignored (help) - ↑ 19.0 19.1 Sharma AK, Ajani AE, Hamwi SM, Maniar P, Lakhani SV, Waksman R, Lindsay J (2004). "Major noncardiac surgery following coronary stenting: when is it safe to operate?". Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions. 63 (2): 141–5. doi:10.1002/ccd.20124. PMID 15390248. Retrieved 2011-12-08. Unknown parameter
|month=
ignored (help) - ↑ 20.0 20.1 Kałuza GL, Joseph J, Lee JR, Raizner ME, Raizner AE (2000). "Catastrophic outcomes of noncardiac surgery soon after coronary stenting". Journal of the American College of Cardiology. 35 (5): 1288–94. PMID 10758971. Retrieved 2011-12-08. Unknown parameter
|month=
ignored (help) - ↑ Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, Granada JF, Marulkar S, Nassif D, Cohen DJ, Kleiman NS (2007). "Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents". JAMA : the Journal of the American Medical Association. 297 (18): 2001–9. doi:10.1001/jama.297.18.2001. PMID 17488965. Retrieved 2011-12-08. Unknown parameter
|month=
ignored (help) - ↑ Berger PB, Bell MR, Hasdai D, Grill DE, Melby S, Holmes DR (1999). "Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement". Circulation. 99 (2): 248–53. PMID 9892591. Retrieved 2011-12-08. Unknown parameter
|month=
ignored (help) - ↑ Cruden NL, Harding SA, Flapan AD, Graham C, Wild SH, Slack R, Pell JP, Newby DE (2010). "Previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery". Circulation. Cardiovascular Interventions. 3 (3): 236–42. doi:10.1161/CIRCINTERVENTIONS.109.934703. PMID 20442357. Retrieved 2011-12-08. Unknown parameter
|month=
ignored (help) - ↑ 24.0 24.1 Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof EL, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF (2009). "2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery". Journal of the American College of Cardiology. 54 (22): e13–e118. doi:10.1016/j.jacc.2009.07.010. PMID 19926002. Retrieved 2011-12-08. Unknown parameter
|month=
ignored (help) - ↑ Reddy PR, Vaitkus PT (2005). "Risks of noncardiac surgery after coronary stenting". The American Journal of Cardiology. 95 (6): 755–7. doi:10.1016/j.amjcard.2004.11.029. PMID 15757604. Retrieved 2011-12-08. Unknown parameter
|month=
ignored (help) - ↑ Wilson SH, Fasseas P, Orford JL, Lennon RJ, Horlocker T, Charnoff NE, Melby S, Berger PB (2003). "Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting". Journal of the American College of Cardiology. 42 (2): 234–40. PMID 12875757. Retrieved 2011-12-08. Unknown parameter
|month=
ignored (help)
- Pages with reference errors
- Pages using duplicate arguments in template calls
- Pages with citations using unsupported parameters
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- Pages using citations with accessdate and no URL
- Pages with citations using unnamed parameters
- Cardiology
- Surgery